Ollivier Legrand

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigné, Cécile Pautas, Christine Terré et al. · The Lancet · 2012 · 975 citations

Hematological Malignancy, Oncology, Gemtuzumab Ozogamicin +8

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Juliette Lambert, Cécile Pautas, Christine Terré et al. · Haematologica · 2018 · 336 citations · Full text

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

A.-L. Taksin, Ollivier Legrand, Emmanuel Raffoux et al. · Leukemia · 2006 · 282 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10

Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in Adult Acute Myeloid Leukemia Patients

Ollivier Legrand, Ghislaine Simonin, Jean‐Yves Perrot et al. · Blood · 1998 · 201 citations

Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias

Zineb Benderra, Anne‐Marie Faussat, Lydia Sayada et al. · Clinical Cancer Research · 2004 · 185 citations